|
?:abstract
|
-
Aim To investigate the impact of patient immune status on the severity of COVID-19 Materials and methods The prospective study included 63 employees of the V I Kulakov NMRC for OG&P of Minzdrav of Russia with confirmed COVID-19 The patients were stratified into three groups based on the disease severity, including asymptomatic (group 1, n=17), mild (group 2, n=29), and moderate (group 3, n=17) form of COVID-19 On days 3–7 from the onset of the disease, peripheral venous blood samples were collected from the study subjects and tested for serum levels of anti-SARS-CoV-2 IgG antibodies and immune profile by ELISA After day 20+, testing for serum levels of anti-SARS-CoV-2 IgG antibodies was repeated using ELISA Results Patients who had a higher BMI, blood group A(II), lower leukocyte and lymphocyte counts, higher relative monocyte count, changes in the immune profile in the form of a lower number of CD3+, CD3+ CD8+, СD19+, CD19+ CD5+, and phagocytic activity of neutrophils, developed more severe forms of COVID-19 They had severe clinical manifestations of the disease, and 100% of them developed antiviral immunity Conclusion This study identified several clinical, laboratory, and immune profile features that may be considered as predictive factors of severe COVID-19 and can be used in clinical practice to predict the clinical course of the disease
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}